Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Comprehensive Cancer Center of Wake Forest University Identifier:
First received: November 1, 1999
Last updated: July 12, 2012
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2003
  Primary Completion Date: January 2000 (Final data collection date for primary outcome measure)
Acostamadiedo J, Case D, Perry J, et al.: Randomized trial of G-CSF primed (G') autologous bone marrow (ABM) vs. G' peripheral blood stem cells (PBSC) as hematopoietic support after high-dose cyclophosphamide (C) thiotepa (T), and carboplatin (CB) (CTCB) in poor prognosis breast cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A215, 56a, 2000.